Envestnet Asset Management Inc Aurinia Pharmaceuticals Inc. Transaction History

Envestnet Asset Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$6.66 - $12.39 $22,577 - $42,002	-3,390 Reduced 11.6%	25,838 $194,000
Q2 2022 Aug 03, 2022	BUY	$8.95 - $12.8 $3,678 - $5,260	411 Added 1.43%	29,228 $294,000
Q1 2022 May 04, 2022	SELL	$10.05 - $22.48 $51,295 - $114,737	-5,104 Reduced 15.05%	28,817 $357,000
Q4 2021 Feb 04, 2022	SELL	$17.78 - $33.08 $64,096 - $119,253	-3,605 Reduced 9.61%	33,921 $776,000
Q3 2021 Oct 07, 2021	SELL	$10.93 - $23.55 $117,759 - $253,727	-10,774 Reduced 22.31%	37,526 $830,000
Q2 2021 Aug 04, 2021	BUY	$10.0 - $14.52 $50,920 - $73,935	5,092 Added 11.78%	48,300 $626,000
Q1 2021 May 04, 2021	BUY	$12.3 - $18.73 $531,458 - $809,285	43,208 New	43,208 $561,000

223

59.4M

1.17M

1.54M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.13B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Envestnet Asset Management Inc with notifications on news.